AffaMed Therapeutics

AffaMed Therapeutics is an innovative biopharmaceutical company dedicated to developing and commercializing transformative medicines to address critical unmet medical needs in ophthalmology, neurology, and psychiatry for patients in Greater China and around the world. The management team of AffaMed Therapeutics possesses deep expertise and has a proven track record of success in high-quality clinical development, regulatory affairs, Chemistry, Manufacturing, and Control (CMC), business development, and operations in China as well as with leading global pharmaceutical companies. AffaMed Therapeutics was founded in 2019 with investment from CBC Group.